For MK‐4166, a humanized anti‐hGITR antibody, its murine surrogate mAb(DTA‐1) was used in 4T1 and CT26 tumor models, and the data indicated DTA‐1 alone exhibited no tumor rejection while DTA‐1 combined with anti‐TGF‐β or irradiation induce the synergistic antitumor efficacy [15], and responses were only seen with combination treatment in clinical trials [17]. Here, TGFB1 is linked to neoplasm.